Related Experiment Video

Updated: May 31, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

5th Canadian Melanoma Conference: research frontiers

Léon C van Kempen1

  • 1Department of Pathology, McGill University and Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Cote Ste-Catherine, Montréal, QC, H3T 1E2, Canada. leon.vankempen@mcgill.ca

Expert Review of Anticancer Therapy
|June 29, 2011
PubMed

Insights

Recent advancements offer hope for metastatic melanoma treatment. Early detection and molecular profiling are key to optimizing targeted therapy responses for better patient outcomes.

Area of Science:

  • Oncology
  • Dermatology
  • Immunology

Background:

  • Previous metastatic melanoma treatments showed limited success in improving survival or progression times.
  • Recent scientific meetings indicate a more optimistic outlook for patient treatment.
  • The 5th Canadian Melanoma Conference highlighted progress in melanoma research and treatment.

Framework:

  • The 5th Canadian Melanoma Conference focused on three key themes: basic science and pathology, dermatology and surgery, and immunology and systemic treatment.
  • The conference included presentations on dermoscopy case studies and a symposium on advanced melanoma treatment evaluation.
  • Key themes emphasized early detection and patient stratification for optimized treatment outcomes.

Implementation:

  • The conference highlighted the importance of understanding tumor molecular profiles.
  • Stratification of patients based on molecular characteristics is crucial for effective treatment.

Implications:

  • Optimizing targeted therapy response through early detection and molecular profiling is essential.
  • The findings suggest a more hopeful future for metastatic melanoma patient management and outcomes.

More Related Videos

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models05:33

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models

Published on: September 6, 2024

Imaging- and Flow Cytometry-based Analysis of Cell Position and the Cell Cycle in 3D Melanoma Spheroids10:44

Imaging- and Flow Cytometry-based Analysis of Cell Position and the Cell Cycle in 3D Melanoma Spheroids

Published on: December 28, 2015

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...